Pre-registration UICC – AMGEN WHA79 side event: AI serving better patient outcomes

This side event, convened by the Union for International Cancer Control (UICC) with the support of Amgen, will explore how AI can be integrated into cancer care in ways that genuinely serve patients’ needs. It will bring together perspectives from clinicians, industry, civil society, and global health actors to examine real‑world examples of AI in practice, alongside the governance and assurance mechanisms needed to ensure these technologies are safe, ethical, and trustworthy.

By focusing on responsible deployment rather than technology alone, the event aims to contribute to broader World Health Assembly discussions on digital health and innovation. It will highlight practical approaches to aligning AI development with patient interests, strengthening trust, and promoting equitable access — ensuring that advances in AI translate into meaningful improvements in cancer outcomes for all.

Date and time

21 May 2026, from 10 am to 12:00 noon CEST
during the upcoming World Health Assembly.

Venue

Union for International Cancer Control (UICC)
31-33 Avenue Giuseppe Motta, 1202 Geneva – Switzerland

Please provide your details here below to pre-register

First name

Last name

Job title

Organisation

Country

Contact email:

Confirm email:

Privacy policy

By ticking the box below, I authorise UICC to use the personal data provided to support the logistical organisation of my participation in the event, I also agree to the UICC Privacy policy.

I agree

This event is organised by:

Founded in 1933 and based in Geneva, UICC has over 1150 member organisations in 172 countries and territories. The membership base includes the world’s major cancer leagues and societies, research institutes, treatment centres, hospitals, ministries of health, public health agencies and patient support groups. UICC’s mission is to both unite and support the cancer community in its efforts to reduce the global cancer burden, promote greater equity and ensure that cancer control remains a priority on the global health and development agenda.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Last update

Monday 20 April 2026